This meta- analysis demonstrated that resveratrol supplementation among patients with MetS and related disorders  significantly reduced total cholesterol and increased GGT concentrations , but did not affect triglycerides , LDL- , HDL-cholesterol , ALT , and AST concentrations .
This data suggests that resveratrol may have a potential cardio-protective effect in patients with MetS and related disorders
There are current trials investigating the effect of resveratrol supplementation on lipid profiles and liver enzymes among patients with metabolic syndrome ( MetS ) and related disorders ; however , their findings are controversial .
This systematic review and meta- analysis were aim ed to determine the effects of resveratrol supplementation on lipid profiles and liver enzymes among patients with MetS and related disorders .
Effect of red yeast rice combined with antioxidants on lipid pattern, hs-CRP level, and endothelial function in moderately hypercholesterolemic subjects
Our aim was to test , through a crossover , double-blind , placebo-controlled r and omized clinical trial , if a short-term treatment with 10 mg monacolins combined with antioxidants could improve lipid pattern , high-sensitivity C-reactive protein ( hs-CRP ) , and endothelial function in a small cohort of moderately hypercholesterolemic subjects . Thus , 25 healthy , moderately hypercholesterolemic subjects were consecutively enrolled and , after 4 weeks of stabilization diet , were r and omized to the sequence placebo followed by a washout , monacolins or monacolins followed by a washout , placebo , with each period being 4 weeks long . At each study step , a complete lipid pattern , safety parameters , hs-CRP , and endothelial function have been measured . When compared to the placebo phase , during monacolin treatment , patients experienced a more favorable percentage change in total cholesterol ( TC ) ( TC after monacolin treatment , −18.35 % ; TC after placebo treatment , −5.39 % ) , low-density lipoprotein cholesterol ( LDL-C ) ( LDL after monacolin treatment , −22.36 % ; LDL after placebo treatment , −1.38 % ) , non-high-density lipoprotein cholesterol ( HDL-C ) ( non-HDL after monacolin treatment , −22.83 % ; non-HDL after placebo treatment : −7.15 % ) , hs-CRP ( hs-CRP after monacolin treatment : −2.33 % ; hs-CRP after placebo treatment , 2.11 % ) , and endothelial function ( pulse volume displacement after monacolin treatment , 18.59 % ; pulse volume displacement after placebo treatment , −6.69 % ) . No significant difference was observed with regard to triglycerides , HDL-cholesterol , and safety parameters . On the basis of our data , we could demonstrate that a 10 mg monacolin nutraceutical treatment appears to safely reduce cholesterolemia , hs-CRP , and markers of vascular remodeling in moderately hypercholesterolemic subjects . These results need to be confirmed in larger patient sample s and in studies with longer duration
This meta- analysis demonstrated that resveratrol supplementation among patients with MetS and related disorders  significantly reduced total cholesterol and increased GGT concentrations , but did not affect triglycerides , LDL- , HDL-cholesterol , ALT , and AST concentrations .
This data suggests that resveratrol may have a potential cardio-protective effect in patients with MetS and related disorders
There are current trials investigating the effect of resveratrol supplementation on lipid profiles and liver enzymes among patients with metabolic syndrome ( MetS ) and related disorders ; however , their findings are controversial .
This systematic review and meta- analysis were aim ed to determine the effects of resveratrol supplementation on lipid profiles and liver enzymes among patients with MetS and related disorders .